Development and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer

摘要: The current strategy for diagnosing prostate cancer (PCa) is mainly based on the serum prostate-specific antigen (PSA) test. However, PSA has low specificity and led to numerous unnecessary biopsies. We evaluated effectiveness of urinary metastasis-associated lung adenocarcinoma transcript 1 (MALAT-1), a long noncoding RNA, predicting risk PCa before biopsy. MALAT-1 score was tested in discovery phase multi-center validation phase. predictive power by area under receiver operating characteristic (ROC) curve (AUC) decision analysis. As an independent predictor PCa, significantly higher men with positive biopsy than those negative ROC analysis showed AUC (0.670 0.742) vs. total (0.545 0.601) percent free (0.622 0.627) patients values 4.0-10 ng/ml. According analysis, using probability threshold 25%, model would prevent 30.2%-46.5% biopsies 4–10 ng/ml cohorts, without missing any high-grade cancers. Our results demonstrate that urine promising biomarker risk.